Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Tetra Bio Pharma Inc TBPMQ

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to... see more

GREY:TBPMQ - Post Discussion

Tetra Bio Pharma Inc > QIXLEEF reborn trial
View:
Post by Golddetector on Nov 21, 2021 1:40pm

QIXLEEF reborn trial

Some of comments by short sellers here are laughable. Do these clowns even think that anyone believes the garbage they post. Go to fda website and check reborn started may 2021 and need 20 patients only against 3 oral opioid. Look up Tetra published q3 d&a We have to active 2 sites to enroll patients. It is already 6 months since started how much longer can it take 2 or 3 more months? This is opioid alternative in the making. is it working. The trial is accelerated and they are focusing on QIXLEEF and Reduvo only so if it is not working why do that? It is big. below a 4 month old video explaining how big. Last pp at 40 cents was oversubscribed because it was a big deal. Now the sp below 25cents is stupid cheap. These clowns hanging around here for a reason. Gl longs
Comment by Davesnothere on Nov 21, 2021 3:46pm
I have been holding TBP for many years. Recently loaded the duelly with a ton more thanks to encouragement from Sean Black. Just a .50 cent move up to around 00.75 / share would be a home run. Anything in the XXX dollars would be hard to imagine !!! But the fun part is that finally , I believe, we are " ANY DAY NOW "  That could be 2 weeks 2 months, or tomorrow. Go Tetra. 
Comment by new2mjstocks on Nov 21, 2021 6:04pm
How many patients enrolled in reborn trial ?
Comment by SamV21 on Nov 21, 2021 10:13pm
Well Detector ,how many ? that is a question , no answer but once again  thanks for the useless pump.
Comment by KVDollars on Nov 22, 2021 11:09am
Sam shut up LOL we get it youre being paid to bash LOL. stop asking your dumb questions,. The moment results drop. You will be gone..  All you bashers always go quiet during a run and when it slows down or goes back down all of you star acting like we are so smart look at us, I hope you have a major short position so when reduvo drops your aszzz gets burnttttttttt
Comment by SamV21 on Nov 22, 2021 11:21am
No I am long I own more than you ahole.
Comment by Golddetector on Nov 21, 2021 9:41pm
Correct two major catalysts QIXLEEF interim and Reduvo anytime now. QIXLEEF will show effectiveness against opioid and Reduvo will generate revenue. Major upside on each one of these. Gl longs
Comment by DONOOW on Nov 22, 2021 5:29am
We will see that there is no updates ,then we will start thinking why ,and imagining something to swallow it,
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities